Showing 4751-4760 of 5964 results for "".
- Crown Laboratories Redesigns Blue Lizard Australian Sunscreen Line to Comply with Reef-Safe Legislationhttps://practicaldermatology.com/news/crown-laboratories-launches-redesigned-blue-lizard-australian-sunscreen-line/2459893/Crown Laboratories, Inc., has relaunched its redesigned, dermatologist-recommended Blue Lizard Australian Sunscreen. The company says the redesign includes new products, improved formulations, and a new aesthetic design concept across the entire portfolio based on a year of research to build on t
- SkinBioTherapeutics Raises Capital to Broaden Applications for Skin Biome Technologyhttps://practicaldermatology.com/news/skinbiotherapeutics-raises-capital-to-broaden-applications-for-skin-biome-technology/2459894/SkinBioTherapeutics raised close to $2M to widen potential applications for their skin biome technology, the company reports. Derived from probiotic bacteria, SkinBioTherapeutics technology is being developed for use in cosmetics, infectio
- FDA Proposes Policy for New Competitive Generic Therapies Pathwayhttps://practicaldermatology.com/news/fda-proposes-policy-for-new-competitive-generic-therapies-pathway/2459896/The FDA has issued a new policy it says is intended to improve access and increase competition for drugs that lack generic competition. The new pathway for Competitive Generic Therapies (CGTs) creates a designation that can be granted to a company submitting an application for their
- Rodan & Fields Takes on Teen Acne with Spotlesshttps://practicaldermatology.com/news/rodan-fields-takes-on-teen-acne-with-spotless/2459898/Rodan & Fields is launching Spotless, a patent-pending teen and young adult acne solution. The company is also updating its Unblemish R
- Sienna Biopharmaceuticals: Promising Topline Results for SNA-001 for Hair Removalhttps://practicaldermatology.com/news/sienna-biopharmaceuticals-promising-topline-results-for-sna-001-for-hair-removal/2459899/Topline results from the pivotal trial of Sienna Biopharmaceuticals’ SNA-001 show that the topical agent in conjunction with an 810nm diode laser was statistically superior compared to vehicle plus laser. In the study involving 65 male and female patients with white, gray, blonde, light red
- Stelatopia Emollient Face Cream Now Available from Mustelahttps://practicaldermatology.com/news/stelatopia-emollient-face-cream-now-available-from-mustela/2459902/Mustela Stelatopia Emollient Face Cream is now available, specifically designed for extremely dry to eczema-prone skin and gentle enough to use on newborns. Formulated with Avocado Perseose®, which is intended to restore and protect the skin barrier by boosting ceramides a
- Applied Biology to Enter into a License Agreement with Hairmore for Novel Traction Alopecia Rxhttps://practicaldermatology.com/news/applied-biology-to-enter-into-a-license-agreement-with-hairmore-for-novel-traction-alopecia-rx/2459904/Applied Biology, Inc. is bringing its novel TAAR receptor agonist for the treatment of traction or ponytail alopecia to the Chinese market through a licensing deal with the Hairmore Group. When applied to the scalp, Applied Biology’s
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- New from BD: Prefillable Glass Syringe for Viscous Solutionshttps://practicaldermatology.com/news/new-from-bd-prefillable-glass-syringe-for-viscous-solutions/2459910/BD (Becton, Dickinson and Company) has presented BD Hylok,its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Pharmapack 2019. BD Hylokis also the first glass pre-fillab
- Vyome Secures $22M to Advance Dermatology Pipelinehttps://practicaldermatology.com/news/vyome-secures-22m-to-advance-dermatology-pipeline/2459918/Vyome Therapeutics Inc., a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, closed $22 million in financing. The company says it plans to primarily use the funds to advance its lead molecule, VB 19